Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical devices, glasses, lens, and vision aid products. It is also involved in leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy services, as well as provides medical and scientific prescription eyeglasses. Furt… Read more
Universal Vision Biotechnology Co Ltd (3218) - Net Assets
Latest net assets as of September 2025: NT$3.87 Billion TWD
Based on the latest financial reports, Universal Vision Biotechnology Co Ltd (3218) has net assets worth NT$3.87 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$5.94 Billion) and total liabilities (NT$2.07 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.87 Billion |
| % of Total Assets | 65.12% |
| Annual Growth Rate | 14.1% |
| 5-Year Change | 84.15% |
| 10-Year Change | 226.66% |
| Growth Volatility | 23.0 |
Universal Vision Biotechnology Co Ltd - Net Assets Trend (2003–2024)
This chart illustrates how Universal Vision Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Universal Vision Biotechnology Co Ltd (2003–2024)
The table below shows the annual net assets of Universal Vision Biotechnology Co Ltd from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.76 Billion | +12.35% |
| 2023-12-31 | NT$3.34 Billion | +18.15% |
| 2022-12-31 | NT$2.83 Billion | +21.51% |
| 2021-12-31 | NT$2.33 Billion | +14.17% |
| 2020-12-31 | NT$2.04 Billion | +20.30% |
| 2019-12-31 | NT$1.70 Billion | +5.37% |
| 2018-12-31 | NT$1.61 Billion | +1.66% |
| 2017-12-31 | NT$1.58 Billion | +36.46% |
| 2016-12-31 | NT$1.16 Billion | +0.88% |
| 2015-12-31 | NT$1.15 Billion | +0.80% |
| 2014-12-31 | NT$1.14 Billion | +3.83% |
| 2013-12-31 | NT$1.10 Billion | +7.88% |
| 2012-12-31 | NT$1.02 Billion | -10.58% |
| 2011-12-31 | NT$1.14 Billion | +71.57% |
| 2010-12-31 | NT$663.76 Million | -2.57% |
| 2009-12-31 | NT$681.29 Million | +26.35% |
| 2008-12-31 | NT$539.22 Million | -10.37% |
| 2007-12-31 | NT$601.63 Million | +10.01% |
| 2006-12-31 | NT$546.91 Million | +78.80% |
| 2004-12-31 | NT$305.87 Million | +29.95% |
| 2003-12-31 | NT$235.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Universal Vision Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7824.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$2.00 Billion | 55.17% |
| Other Components | NT$1.62 Billion | 44.83% |
| Total Equity | NT$3.62 Billion | 100.00% |
Universal Vision Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of Universal Vision Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KT Submarine Co. Ltd
KQ:060370
|
$216.61 Million |
|
Lever Global Corporation
OTCQB:LVER
|
$216.61 Million |
|
LOG Commercial Properties e Participações S.A
SA:LOGG3
|
$216.64 Million |
|
Polyrocks Chemical Co Ltd
SHG:688669
|
$216.79 Million |
|
AB Fagerhult
F:2F0
|
$216.55 Million |
|
Bank of Ayudhya PCL
BK:BAY
|
$216.48 Million |
|
Bharat Bijlee Limited
NSE:BBL
|
$216.37 Million |
|
UE Furniture Co Ltd
SHG:603600
|
$216.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Universal Vision Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,177,642,000 to 3,622,013,000, a change of 444,371,000 (14.0%).
- Net income of 1,064,721,000 contributed positively to equity growth.
- Dividend payments of 593,074,000 reduced retained earnings.
- Other comprehensive income increased equity by 11,384,000.
- Other factors decreased equity by 38,660,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$1.06 Billion | +29.4% |
| Dividends Paid | NT$593.07 Million | -16.37% |
| Other Comprehensive Income | NT$11.38 Million | +0.31% |
| Other Changes | NT$-38.66 Million | -1.07% |
| Total Change | NT$- | 13.98% |
Book Value vs Market Value Analysis
This analysis compares Universal Vision Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.71x to 3.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$18.48 | NT$142.50 | x |
| 2018-12-31 | NT$19.40 | NT$142.50 | x |
| 2019-12-31 | NT$18.73 | NT$142.50 | x |
| 2020-12-31 | NT$22.55 | NT$142.50 | x |
| 2021-12-31 | NT$25.80 | NT$142.50 | x |
| 2022-12-31 | NT$31.40 | NT$142.50 | x |
| 2023-12-31 | NT$37.43 | NT$142.50 | x |
| 2024-12-31 | NT$42.75 | NT$142.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Universal Vision Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 29.40%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.18%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.59x
- Recent ROE (29.40%) is above the historical average (16.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 10.45% | 13.17% | 0.61x | 1.31x | NT$1.06 Million |
| 2004 | 23.94% | 23.04% | 0.83x | 1.25x | NT$42.63 Million |
| 2006 | 12.33% | 20.06% | 0.56x | 1.10x | NT$12.72 Million |
| 2007 | 10.14% | 15.37% | 0.56x | 1.17x | NT$846.30K |
| 2011 | 2.46% | 3.37% | 0.60x | 1.21x | NT$-85.90 Million |
| 2013 | 7.87% | 10.13% | 0.63x | 1.24x | NT$-23.37 Million |
| 2014 | 8.90% | 10.28% | 0.55x | 1.58x | NT$-12.50 Million |
| 2015 | 7.05% | 7.99% | 0.54x | 1.64x | NT$-33.91 Million |
| 2016 | 7.92% | 8.56% | 0.62x | 1.50x | NT$-24.18 Million |
| 2017 | 8.53% | 11.09% | 0.54x | 1.42x | NT$-20.61 Million |
| 2018 | 10.93% | 13.51% | 0.57x | 1.42x | NT$13.80 Million |
| 2019 | 14.96% | 16.77% | 0.54x | 1.66x | NT$78.87 Million |
| 2020 | 25.25% | 23.54% | 0.65x | 1.66x | NT$291.82 Million |
| 2021 | 27.21% | 22.62% | 0.70x | 1.71x | NT$376.59 Million |
| 2022 | 31.92% | 24.34% | 0.78x | 1.69x | NT$584.10 Million |
| 2023 | 32.89% | 25.60% | 0.80x | 1.61x | NT$727.33 Million |
| 2024 | 29.40% | 25.18% | 0.73x | 1.59x | NT$702.52 Million |
Industry Comparison
This section compares Universal Vision Biotechnology Co Ltd's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $508,031,000
- Average return on equity (ROE) among peers: 2.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Universal Vision Biotechnology Co Ltd (3218) | NT$3.87 Billion | 10.45% | 0.54x | $216.57 Million |
| Ma Kuang Healthcare Holding Ltd (4139) | $508.03 Million | 2.02% | 1.78x | $18.00 Million |